Equity Profile

ZTS

Zoetis Inc.

Health CarePharmaceuticals$33.3B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Zoetis Inc. (ZTS) is a leading global animal health company that develops and manufactures medicines and vaccines for pets and livestock....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will help gauge how well Zoetis is managing costs and generating revenue.

N/A

Revenue Growth

Revenue growth is critical for assessing the company's ability to expand its market share and respond to industry trends.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ZTS Q2-2026 Earnings Preview

Context

Company Snapshot

Zoetis Inc. (ZTS) is a leading global animal health company that develops and manufactures medicines and vaccines for pets and livestock. With a market cap of $33 billion, Zoetis plays a crucial role in the health care sector by ensuring the well-being of animals, which is increasingly important as the global demand for animal protein rises.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+4.50%

Avg Stock Reaction

-6.18%

Last Quarter Recap

In Q1 2026, Zoetis reported an EPS of $1.53, which was below expectations, leading to a significant drop in stock price the following day. This miss raised concerns about the company's growth trajectory and operational efficiency.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, analysts are cautious about Zoetis's upcoming earnings due to the recent EPS miss and the lack of management guidance. Investors will be closely watching how the company addresses these challenges.

Bull Case

If Zoetis can demonstrate strong revenue growth and improved margins, it could restore investor confidence and lead to a positive stock reaction.

Bear Case

Conversely, if the company fails to provide clear guidance or reports another earnings miss, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific revenue growth figures can Zoetis provide for its key product segments?

This will help investors assess the company's ability to capture market share and respond to demand in the animal health sector.

How is Zoetis addressing operational challenges that led to the recent EPS miss?

Understanding management's strategies for improving efficiency will be crucial for investor confidence moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Zoetis's ability to rebound from its recent earnings miss, as the company's strong product pipeline could drive unexpected growth.

Supporting Evidence

Options are pricing a 3.68% move, but the stock has averaged 7.68% in past quarters, indicating potential for a larger reaction.

The recent EPS miss may have created a buying opportunity for long-term investors looking for recovery.

Key Risk

If Zoetis reports revenue growth above 5%, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around Zoetis's ability to grow revenue amidst operational challenges and market dynamics.

Bull Confirmed If

Demonstrating revenue growth of at least 5% year-over-year would confirm the bull case.

Bear Confirmed If

If revenue growth is below 2%, it would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±3.68%

Historical Avg

±7.68%

Pricing cheap

The options market is pricing in a modest move, suggesting that investors are uncertain about the upcoming earnings results.

Options are pricing a smaller move than the historical average, indicating potential for a larger actual move.

Detail

ATM IV

0.5%

30d HV

77.9%

Calls (177K)P/C Ratio: 1.05Puts (644K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing cheap setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Zoetis beats expectations, history suggests a potential stock increase of around 3.1%, confirming a positive growth outlook.

In-Line / Cautious

If results are in line but cautious, the stock may remain volatile as investors digest management's commentary.

Miss

A miss could lead to a significant drop, with history suggesting an average decline of 21.50% following such outcomes.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

2 buys·1 sell

Members

House only

Est. Notional

$3,003.00–$45,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on revenue growth by product segment, especially in key markets.
2Management's plans for addressing operational inefficiencies.
3Updates on new product launches and their expected impact on revenue.
4Any insights into market trends affecting animal health.
5Guidance on future earnings and strategic priorities.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Zoetis Inc. (ZTS) is a leading global animal health company that develops and manufactures medicines and vaccines for pets and livestock....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will help gauge how well Zoetis is managing costs and generating revenue.

N/A

Revenue Growth

Revenue growth is critical for assessing the company's ability to expand its market share and respond to industry trends.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ZTS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+4.50%

Avg Stock Reaction

-6.18%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Zoetis can demonstrate strong revenue growth and improved margins, it could restore investor confidence and lead to a positive stock reaction.

Bear Case

Conversely, if the company fails to provide clear guidance or reports another earnings miss, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific revenue growth figures can Zoetis provide for its key product segments?

This will help investors assess the company's ability to capture market share and respond to demand in the animal health sector.

How is Zoetis addressing operational challenges that led to the recent EPS miss?

Understanding management's strategies for improving efficiency will be crucial for investor confidence moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Zoetis's ability to rebound from its recent earnings miss, as the company's strong product pipeline could drive unexpected growth.

Supporting Evidence

Options are pricing a 3.68% move, but the stock has averaged 7.68% in past quarters, indicating potential for a larger reaction.

The recent EPS miss may have created a buying opportunity for long-term investors looking for recovery.

Key Risk

If Zoetis reports revenue growth above 5%, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around Zoetis's ability to grow revenue amidst operational challenges and market dynamics.

Bull Confirmed If

Demonstrating revenue growth of at least 5% year-over-year would confirm the bull case.

Bear Confirmed If

If revenue growth is below 2%, it would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±3.68%

Historical Avg

±7.68%

Pricing cheap

The options market is pricing in a modest move, suggesting that investors are uncertain about the upcoming earnings results.

Options are pricing a smaller move than the historical average, indicating potential for a larger actual move.

Detail

ATM IV

0.5%

30d HV

77.9%

Calls (177K)P/C Ratio: 1.05Puts (644K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing cheap setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Zoetis beats expectations, history suggests a potential stock increase of around 3.1%, confirming a positive growth outlook.

In-Line / Cautious

If results are in line but cautious, the stock may remain volatile as investors digest management's commentary.

Miss

A miss could lead to a significant drop, with history suggesting an average decline of 21.50% following such outcomes.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

2 buys·1 sell

Members

House only

Est. Notional

$3,003.00–$45,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on revenue growth by product segment, especially in key markets.
2Management's plans for addressing operational inefficiencies.
3Updates on new product launches and their expected impact on revenue.
4Any insights into market trends affecting animal health.
5Guidance on future earnings and strategic priorities.